PTLF.US Petlife Pharmaceuticals Inc
- Market cap
- USD 19.7K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Feb 2018.
Is PTLF.US undervalued?
Graham numberThe Graham number of Petlife Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Petlife Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Petlife Pharmaceuticals Inc yet.
Petlife Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Petlife Pharmaceuticals Inc
Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company's principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor. …
Full company profilePetlife Pharmaceuticals Inc financial statements
2018 annualized: Fiscal year 2018 is not finished. Income statement and cash flow are annualized from 2 quarters up to Feb 28, 2018, the balance sheet is the latest quarter. Figures change when the annual report is published.
Petlife Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | - | -267K | -222K | -60.1K | -221K | 0.00 | -17.9K | 0.00 |
| Operating Income | -266K | -619K | -84.6K | -887K | -2.58M | -1.68M | -1.51M | -1.93M | -3.69M | -22.7M | -752K |
| EBITDA | -266K | -619K | -84.6K | -625K | -3.23M | -1.44M | -1.51M | -1.93M | -3.69M | -22.9M | -1.45M |
| Net Income | -284K | -233K | -118K | -466K | -2.32M | -1.16M | -1.51M | -1.93M | -3.69M | -23.3M | -1.79M |
| EPS | - | -116,434 | -59,203 | -73 | -76 | -12 | -0.19 | -0.17 | -0.40 | -0.34 | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 4.36K | 5.00K | 434.00 | 795K | 776K | - | 17.4K | 5.40K | 1.17K | 55.0K | 7.86K |
| Total Liabilities | 540K | 456K | 563K | 463K | 1.31M | - | - | 371K | 3.24M | 1.44M | 1.98M |
| Shareholders' Equity | -536K | -451K | -562K | 308K | 383K | - | 17.4K | -365K | -3.23M | -1.38M | -1.97M |
| Cash & Short-term Investments | - | - | - | 55.9K | 10.1K | - | 6.85K | - | 1.17K | 54.3K | 7.86K |
| Total Debt | 202K | - | - | 265K | 138K | 138K | - | - | 153K | 717K | 802K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -253K | -300K | -31.9K | -141K | -400K | -137K | -267K | -22.0K | -152K | -319K | -565K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 169K | 37.0K | 3.00 | 600.00 | 600.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -253K | -300K | -31.9K | -310K | -437K | -137K | -267K | -22.6K | -152K | -319K | -565K |
| Ratios | |||||||||||
| ROE | - | - | - | -151.6% | -606.2% | - | -8,673.0% | - | - | - | - |
| ROA | -6,521.4% | -4,657.3% | -27,282.3% | -58.6% | -298.8% | - | -8,673.0% | -35,781.5% | -314,593.9% | -42,282.1% | -22,752.6% |
| Debt to Equity | - | - | - | 0.86x | 0.36x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Petlife Pharmaceuticals Inc dividends
Petlife Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Sep 12, 2016.
Who owns Petlife Pharmaceuticals Inc
- Insiders 6.43%
- Institutions 0.00%
- Public & others 93.57%
- Shares outstanding 197M
- Free float 72.3M
Petlife Pharmaceuticals Inc company profile
- Company name
- Petlife Pharmaceuticals Inc
- Ticker
- PTLF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1
- Fiscal year end
- August
- Address
- 8033 Sunset Boulevard, Los Angeles, CA, United States, 90046
- Phone
- 424-216-6807
- Website
- -
About Petlife Pharmaceuticals Inc
Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company's principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor. In addition, the company develops edible dog and cat treats. Petlife Pharmaceuticals, Inc. is based in Los Angeles, California.
Petlife Pharmaceuticals Inc management
2- Mr. Sebastian Serrell-WattsChairman, CEO, President, CFO, Secretary & Treasurer · born 1965
- Dr. Arthur Grant Mikaelian Ph.D.Founder and Chief Scientific Officer · born 1962